NEW YORK / Oct 23, 2023 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 after the markets close on Monday, November 6, 2023. Management will also host a conference call to discuss these results at 5:00 p.m. EDT on that day.
Conference call and webcast details:
Monday, November 6, 2023
5:00 p.m. EDT
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13741345
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$4.10 |
Daily Change: | 0.08 1.99 |
Daily Volume: | 359,505 |
Market Cap: | US$419.510M |
November 07, 2024 October 09, 2024 September 19, 2024 August 07, 2024 August 05, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB